Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleMetabolism, Transport, and Pharmacogenomics

Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032)

Rajendar K. Mittapalli, Shruthi Vaidhyanathan, Ramola Sane and William F. Elmquist
Journal of Pharmacology and Experimental Therapeutics July 2012, 342 (1) 33-40; DOI: https://doi.org/10.1124/jpet.112.192195
Rajendar K. Mittapalli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shruthi Vaidhyanathan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramola Sane
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William F. Elmquist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 342 no. 1 33-40
DOI 
https://doi.org/10.1124/jpet.112.192195
PubMed 
22454535

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received January 17, 2012
  • Accepted March 26, 2012
  • Published online June 15, 2012.

Article Versions

  • Earlier version (March 27, 2012 - 06:57).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Rajendar K. Mittapalli,
  2. Shruthi Vaidhyanathan,
  3. Ramola Sane and
  4. William F. Elmquist
  1. Department of Pharmaceutics, Brain Barriers Research Center, University of Minnesota, Minneapolis, Minnesota
  1. Address correspondence to:
    William F. Elmquist, Department of Pharmaceutics, University of Minnesota, 9-177 Weaver Densford Hall, 308 Harvard Street SE, Minneapolis, MN 55455. E-mail: elmqu011{at}umn.edu
  1. R.K.M. and S.V. contributed equally to this work.

View Full Text

Statistics from Altmetric.com

Article usage

Article usage: March 2012 to May 2022

AbstractFullPdf
Mar 20121630384
Apr 20121750275
May 2012930793
Jun 201249427140
Jul 20123844891
Aug 20121583450
Sep 20121311834
Oct 2012723543
Nov 2012962436
Dec 2012503446
Jan 2013601926
Feb 2013681119
Mar 2013501313
Apr 2013501224
May 2013631730
Jun 201334612
Jul 2013391429
Aug 2013381521
Sep 2013511828
Oct 2013451223
Nov 2013341829
Dec 2013222338
Jan 2014181414
Feb 2014222520
Mar 2014251318
Apr 2014242220
May 2014191722
Jun 2014351618
Jul 201423149
Aug 2014221413
Sep 2014311315
Oct 2014181012
Nov 2014201312
Dec 201418914
Jan 20151185
Feb 2015321011
Mar 201523710
Apr 201516911
May 201513910
Jun 2015181112
Jul 2015311329
Aug 201519814
Sep 2015161214
Oct 2015151010
Nov 2015251215
Dec 20152096
Jan 2016241518
Feb 201625917
Mar 2016421228
Apr 20161458
May 201611611
Jun 201625710
Jul 2016421213
Aug 2016331918
Sep 201616910
Oct 2016192116
Nov 201692210
Dec 20165225
Jan 2017133214
Feb 20172243
Mar 201793812
Apr 201742215
May 201711717
Jun 20172121
Jul 20174136
Aug 201723211
Sep 201751812
Oct 201723024
Nov 2017112530
Dec 201772610
Jan 201873215
Feb 201842714
Mar 201841812
Apr 201853010
May 201851515
Jun 201821512
Jul 201831812
Aug 20183185
Sep 2018112913
Oct 201833213
Nov 201835614
Dec 20183874
Jan 20194633
Feb 20196423
Mar 20193763
Apr 20194223
May 20192423
Jun 20191715
Jul 20192502
Aug 20191832
Sep 20192700
Oct 20191511
Nov 20192610
Dec 20191663
Jan 20201463
Feb 20201631
Mar 20203343
Apr 20201052
May 2020310
Jun 20203223
Jul 20201211
Aug 20201127
Sep 20202221
Oct 20203362
Nov 20202842
Dec 20201941
Jan 202123198
Feb 202118225
Mar 202146122
Apr 20211563
May 20214496
Jun 2021981
Jul 20211786
Aug 202118101
Sep 202129154
Oct 20213362
Nov 20213312
Dec 20212725
Jan 20222178
Feb 20222123
Mar 20221521
Apr 20221346
May 2022544

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 342 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 342, Issue 1
1 Jul 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032)
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleMetabolism, Transport, and Pharmacogenomics

P-gp and Bcrp Restrict Brain Distribution of Vemurafenib

Rajendar K. Mittapalli, Shruthi Vaidhyanathan, Ramola Sane and William F. Elmquist
Journal of Pharmacology and Experimental Therapeutics July 1, 2012, 342 (1) 33-40; DOI: https://doi.org/10.1124/jpet.112.192195

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleMetabolism, Transport, and Pharmacogenomics

P-gp and Bcrp Restrict Brain Distribution of Vemurafenib

Rajendar K. Mittapalli, Shruthi Vaidhyanathan, Ramola Sane and William F. Elmquist
Journal of Pharmacology and Experimental Therapeutics July 1, 2012, 342 (1) 33-40; DOI: https://doi.org/10.1124/jpet.112.192195
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • HDL Mimetic 4F Modulates Aβ Distribution in Brain and Plasma
  • AOX1 Inhibition by Gefitinib, Erlotinib, and Metabolites
  • Catalytic Activity of CYP2C9 Variants
Show more Metabolism, Transport, and Pharmacogenomics

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics